问题是:Breyanzi的数据是否足以支持FDA的申请?如果被批准,它们会对CLL治疗产生影响吗? 目前,由于没有具体细节,仍不清楚。 Still, because CLL patients are typically older and have undergone significant treatment, their immune systems may be impaired, making them less-than-ideal candidates for CAR-T treatment.